Argos Therapeutics Participating In 4th International MRNA Health Conference

DURHAM, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company is participating in the 4 th International mRNA Health Conference being held November 1-2 at the Westin Boston Waterfront in Boston, Massachusetts.

Irina Tcherepanova, Ph.D., senior director of research and development for Argos, presented a poster titled, "Development of a Novel, Rapid Assay to Test the Quality of In-vitro Transcribed Amplified Tumor RNA."

"This work describes a way to quantitatively determine the quality of RNA used in clinical trials and could be an important quality control test in the emerging field of RNA-based therapeutics," stated Dr. Tcherepanova.

The International mRNA Health Conference is an annual forum dedicated to the expanding field of therapeutic mRNA. The conference is attended by researchers and professionals working with mRNA for medical purposes or seeking mRNA as a novel tool to express proteins directly in situ. For more information visit http://www.mrna-conference.com/.

About the Arcelis® Technology Platform Arcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient's individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient's own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient's plasma, and administered via intradermal injection as an individualized immunotherapy.

If you liked this article you might like

S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon'

Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes

Argos Therapeutics Tanks on Committee Suggestion to Stop Carcinoma Drug Study

Stock Futures Waver as Wall Street Awaits Clarity From the Fed

Argos Plummets 72%, Leads Biotech Movers